Biotech Values

[RNsidersbuying]

LPTN .30 News - with .56 hard cash remaining:

SAN DIEGO, July 23, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab™. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.

http://ih.advfn.com/p.php?pid=nmona&article=67842617&symbol=LPTN